• Ticker

    Advertisement Find a Broker - Visit the DailyFinance Broker Center
DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$9.79 -$0.11 (-1.11%)

REAL-TIME: Last trade at

ISIS Pharmaceuticals, Inc.

NASDAQ:ISIS

Jump to this page for:

Related Resources

Isis Loss Widens on Higher Expenses - Analyst Blog

5/9/2012 by Nasdaq

Johnson & Johnson Raises Forecast; Will Other Drug Companies Follow Suit?

4/18/2012 by DailyFinance

Biogen Inks Deal with MAKScientific - Analyst Blog

3/19/2012 by Nasdaq

Isis Loss Widens; Focus on Kynamro - Analyst Blog

3/2/2012 by Nasdaq

Biogen to Buy Stromedix - Analyst Blog

2/17/2012 by Nasdaq

Alnylam Delivers In-Line Numbers - Analyst Blog

2/13/2012 by Nasdaq

The Zacks Analyst Blog Highlights: General Motors, Toyota Motor, Ford Motor, Biogen Idec and Isis Ph

1/13/2012 by Nasdaq

Isis-Biogen Team Up - Analyst Blog

1/12/2012 by Nasdaq

Biogen, Isis Enter Collaboration On Spinal Atrophy Treatment

1/4/2012 by Smart Money

Pfizer Nets Excaliard Pharma - Analyst Blog

12/5/2011 by Nasdaq

Back to Neutral on Isis Pharma - Analyst Blog

11/29/2011 by Nasdaq

Pfizer Signs Another Deal - Analyst Blog

11/23/2011 by Nasdaq

Pfizer Adds to Fibrosis Drug Pipeline With Excaliard Buyout

11/22/2011 by DailyFinance

Morning Roundup: Today's Top Stories

11/22/2011 by DailyFinance

Pfizer Acquires Excaliard, an Isis Spinout With Drug to Fight Excessive Scarring

11/22/2011 by DailyFinance

Mid-Day Update: Stocks Lower at Session's Half; Revised GDP Data Weighs on Sentiment

11/22/2011 by Nasdaq

Cubist Squares Well With These 2 Metrics

11/20/2011 by DailyFinance

Sanofi, Regeneron's Anti-Cholesterol Drug Has Good Test Results

11/10/2011 by Smart Money

Isis Pharmaceuticals' Shares Plunged: What You Need to Know

11/8/2011 by DailyFinance

The Fool Looks Ahead

11/5/2011 by DailyFinance

Hearty Profits: Companies Racing to Develop the Next Big Cholesterol Drug

8/30/2011 by Nasdaq

2 Positive Signs for Cubist Pharmaceuticals

8/20/2011 by DailyFinance

ISIS Pharmaceuticals' CEO Discusses Q2 2011 Results - Earnings Call Transcript

8/4/2011 by Seeking Alpha Transcripts

Sanofi Sales Helped by Genzyme

7/28/2011 by Minyanville

Bristol-Myers, AstraZeneca Dealt Setback on Diabetes Drug

7/20/2011 by Minyanville

Rebound Ideas: 7 Oversold Stocks With Sufficient Cash to Cover Operating Expenses

5/10/2011 by Seeking Alpha

Top Biotech Picks by Hedge Fund and Mutual Fund Gurus Concentrated in the Sector

5/9/2011 by Seeking Alpha

Isis Pharmaceuticals' CEO Discusses Q1 2011 Results - Earnings Call Transcript

5/5/2011 by Seeking Alpha Transcripts

Isis Pharmaceuticals' CEO Discusses Q1 2011 Results - Earnings Call Transcript

5/5/2011 by Seeking Alpha

Isis Pharmaceuticals: A Lot Riding on Safety of New Drug

4/5/2011 by Seeking Alpha

China Biotech in Review: U.S. Charges 4 China API Makers With Price-Fixing

3/21/2011 by Seeking Alpha

Contrarian Idea: 20 Stocks With Bullish SMA50/SMA200 Trend And Bullish Options Sentiment

3/17/2011 by Nasdaq

Top 30 Most Undervalued, Underperforming Stocks

3/1/2011 by Seeking Alpha

Battered but Unbroken Biotechs

2/28/2011 by Seeking Alpha

Isis Pharmaceuticals CEO Discusses Q4 2010 Results - Earnings Call Transcript

2/28/2011 by Seeking Alpha Transcripts

Isis Pharmaceuticals CEO Discusses Q4 2010 Results - Earnings Call Transcript

2/28/2011 by Seeking Alpha

Sanofi Deal Brings Risk, Opportunity To Genzyme Partners

2/16/2011 by Smart Money

Do Mergers Mean Billions for Biotech?

2/16/2011 by Seeking Alpha

Do Mergers Means Billions for Biotech?

2/16/2011 by Seeking Alpha

FDA Rejection Would Take Isis Stock Down

2/3/2011 by Seeking Alpha
See More Articles...